A Phase 4 interventional study of Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-04-23.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.
Among the 42 studies testing travoprost in Glaucoma, this one is the 9th largest by enrollment of the 39 interventional ones that give a count, is one of 7 that started in 2008, is one of 25 in phase 4, and was the 17th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 231 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 89 across the 39 interventional studies. Of the 41 that completed or were terminated, 18 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
93 studies in Glaucoma by Alcon: none open now, none under way, none of them phase 3. Of 92 finished, 35 (38%) have results posted.
Among the 93 studies in Glaucoma by Alcon, this one is the 19th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2008, is one of 37 in phase 4, and was the 37th registered.
Alcon’s Glaucoma studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 42 studies testing travoprost in Glaucoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 93 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop self-administered in the study eye(s) once daily at night for 12 weeks
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
One drop self-administered in the study eye(s) once daily at night for 12 weeks
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Drug page: Travoprost
Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
Also known as: TRAVATAN Z®, travoprost
Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
Also known as: XALATAN®, latanoprost
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT)
Tear film break-up time was assessed by the same examiner both visits using the same slitlamp/settings. Examiner instilled fluorescein onto the patient's eye, after which the patient blinked several times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to time the occurrence of the first break in the fluorescein film. Three consecutive measurements were taken and averaged for actual TBUT. TBUT at Baseline (Day 0) was subtracted from TBUT at 12 weeks (Day 84) and reported as change. A higher number represents a lengthening in the tear film break up time.
Time frame: 12 weeks (Day 84)
Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 12-week OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.
Time frame: 12 weeks (Day 84)
Patients were recruited from 21 US study centers. Eligible patients having a diagnosis of open-angle glaucoma or ocular hypertension and abnormal TBUT were enrolled.
| Milestone | Travoprost | Latanoprost |
|---|---|---|
| Started | 116 | 115 |
| Completed | 112 | 114 |
| Not completed | 4 | 1 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Tear film break-up time was assessed by the same examiner both visits using the same slitlamp/settings. Examiner instilled fluorescein onto the patient's eye, after which the patient blinked several times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to time the occurrence of the first break in the fluorescein film. Three consecutive measurements were taken and averaged for actual TBUT. TBUT at Baseline (Day 0) was subtracted from TBUT at 12 weeks (Day 84) and reported as change. A higher number represents a lengthening in the tear film break up time.
| seconds | Travoprost | Latanoprost |
|---|---|---|
| Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT) | 0.8 ± 1.5 | 1.1 ± 2.7 |
The OSDI is a 12-question validated questionnaire (resultant overall 0-100 score) used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 12-week OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.
| Units on a scale | Travoprost | Latanoprost |
|---|---|---|
| Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score | -0.0 ± 11.4 | -1.3 ± 16.7 |
Collected over Adverse events were collected for the duration of the study: 11 July 2008 through 03 August 2009.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travoprost | — | 1/116 (0.9%) | 0/116 (0%) |
| Latanoprost | — | 1/115 (0.9%) | 0/115 (0%) |
| Event | Travoprost | Latanoprost |
|---|---|---|
| Gastrointestinal DisorderGastrointestinal disorders | 0/116 | 1/115 |
| CellulitisInfections and infestations | 1/116 | 0/115 |
| Age, Categorical(Participants) | Travoprost | Latanoprost | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 34 | 44 | 78 |
| >=65 years | 78 | 70 | 148 |
| Sex: Female, Male(Participants) | Travoprost | Latanoprost | Total |
|---|---|---|---|
| Female | 74 | 66 | 140 |
| Male | 38 | 48 | 86 |
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost